Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00640484 · ClinicalTrials.gov registry record · Phase 2
Confirmatory Dose Finding Study of 2 Dosages of CHF 4226 pMDI (Carmoterol) in Patients With COPD
A Phase 2 study of Chronic Obstructive Pulmonary Disease, sponsored by Chiesi Farmaceutici S.p.A..
- Completed
- Registry status
- Phase 2
- Development phase
- 57
- Enrollment target
- 15
- Study locations
NCT00640484 is a Phase 2 study of Chronic Obstructive Pulmonary Disease that has completed, run by Chiesi Farmaceutici S.p.A.. The registered enrollment target is 57 participants, below the 1,753-participant average among 86 other Chronic Obstructive Pulmonary Disease trials with a reported enrollment target (97% lower). The trial reports 15 study locations across 13 states.
The verdict
NCT00640484, a Phase 2 study of Chronic Obstructive Pulmonary Disease, has completed, sponsored by Chiesi Farmaceutici S.p.A..
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 57 participants
- Enrollment target
- 15
- Study locations
Study Summary
The purpose of this study is to confirm the dose of CHF 4226 (carmoterol) that should be given once a day to patients with COPD in order for the effect to last for 24 hours.
Conditions Studied
Interventions
- DRUG placebo
- DRUG carmoterol (CHF 4226)
- DRUG salmeterol
Study Locations (15)
Arizona
- Horizon Clinical Research Associates, PLLC - Gilbert
- Pulmonary Associates, PA - Phoenix
Oregon
- Clinical Research Institute of Southern Oregon, PC - Medford
- Asthma Allergy Associates - Portland
California
- UCLA David Geffen School of Medicine - Los Angeles
Florida
- University Clinical Research - DeLand, LLC - DeLand
Georgia
- Pulmonary Medicine and Critical Care - Austell
Illinois
- Sneeze, Wheeze & Itch Associates, LLC - Normal
Kentucky
- Commonwealth BioMedical Research - Madisonville
North Carolina
- North Carolina Clinical Research - Raleigh
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 57 participants |
| Start Date | 2008-04 |
| Est. Completion | 2008-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00640484
The ClinicalTrials.gov registry entry for NCT00640484 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 57 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,753-participant average among 86 other Chronic Obstructive Pulmonary Disease trials with a reported enrollment target (97% lower). The listed sponsor is Chiesi Farmaceutici S.p.A., which has 30 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Chronic Obstructive Pulmonary Disease appearing as the primary indexed condition, and to 3 interventions - of which placebo is the first listed.
NCT00640484 reports 15 study locations spanning 13 distinct geographic areas - top geographies include Arizona, Oregon, California.
Frequently Asked Questions
What is clinical trial NCT00640484 about?
NCT00640484 is a clinical study titled "Confirmatory Dose Finding Study of 2 Dosages of CHF 4226 pMDI (Carmoterol) in Patients With COPD". The purpose of this study is to confirm the dose of CHF 4226 (carmoterol) that should be given once a day to patients with COPD in order for the effect to last for 24 hours.
What is the current status of trial NCT00640484?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 57 participants. The study started on 2008-04. Estimated completion is 2008-10.
What conditions does trial NCT00640484 study?
This clinical trial studies the following conditions: Chronic Obstructive Pulmonary Disease.
What interventions are being tested in trial NCT00640484?
The interventions under investigation include: placebo (DRUG), carmoterol (CHF 4226) (DRUG), salmeterol (DRUG).
Who is sponsoring clinical trial NCT00640484?
This trial is sponsored by Chiesi Farmaceutici S.p.A., which has 30 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00640484 being conducted?
This trial has 15 study locations across Arizona, California, Florida, Georgia, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chronic Obstructive Pulmonary Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Assess the Efficacy and Safety of Verekitug in Participants With COPD
RECRUITING · Phase 2
-
The Cardiovascular Consequences of Sleep Apnea Plus COPD (Overlap Syndrome)
RECRUITING · Phase 2
-
Biological Effects of Quercetin in COPD Phase II
RECRUITING · Phase 2
-
A Phase IIb Ensifentrine-glycopyrrolate Fixed-dose Combination Dose Ranging Study in Subjects With COPD
RECRUITING · Phase 2
-
Breathe Easier With Tadalafil Therapy for Dyspnea in COPD-PH
RECRUITING · Phase 2
-
Inhaled Corticosteroids (ICS) on Pulmonary Endothelial Function in COPD
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.